Dr. Reddy’s Laboratories Ltd. has launched Bosutinib Tablets 400mg, a first-to-market generic equivalent of Wyeth LLC’s Bosulif®, in the United States. As a first-to-file product, the 400mg strength is eligible for 180 days of generic drug exclusivity in the U.S. market.
The launch represents a strategic collaboration with MSN Laboratories Private Limited, which handled the product’s development and manufacturing. Dr. Reddy’s retains exclusive marketing rights within the U.S.. According to IQVIA data, the Bosulif® 400mg brand achieved approximately $253.8 million in U.S. sales for the 12-month period ending April 2026.
“This launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers,” said Milan Kalawadia, CEO- North America, Dr. Reddy’s Laboratories, Inc.
Bharat Reddy, Executive Director of MSN Laboratories, added that the achievement demonstrates MSN’s strong scientific, regulatory, and manufacturing capabilities in delivering complex oncology products. The launch underscores both companies’ shared goal of expanding access to affordable, high-quality cancer treatments.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
